The Cigna Group Q3 FY2026 earnings call

Strategic Vision and Execution:

• Management reaffirmed the 'Lead to One' vision, focusing on delivering personalization at scale to improve affordability and outcomes for complex patients.
• Emphasized three strategic pillars: delivering core growth, leveraging distinct capabilities, and executing with discipline.
• Highlighted strong client retention in the high 90s and robust new business wins for the 2027 season.

Operational Highlights - Evernorth:

• Specialty and Care Services grew 15% year-over-year, driven by secular tailwinds and disciplined execution in specialty pharmacy and distribution.
• Revlimid specialty generic adoption reached approximately 90%.
• Expanded capacity for limited distribution products with a fifth clean room currently in the build phase.
• Launched Evernorth Wholesale and continued to grow CuraScript SD, which has access to 40 exclusive distribution drugs.

Operational Highlights - Pharmacy Benefits Services (PBS):

• Advanced the 'Signature' model implementation, completing the design phase and moving into the build and adoption phases.
• Price Assure capability is live for ~10% of clients; full adoption for Cigna Healthcare Fully Insured book targeted for January 1, 2027, with broader ramp expected in 2028.
• Model aligns with regulatory changes, including the Consolidated Appropriations Act of 2026 and DOL PBM fee disclosure rules.

Operational Highlights - Cigna Healthcare:

• Introduced 'HealthSense,' a data and technology-powered customer engagement solution starting with oncology.
• Medical cost trends remain elevated but stable, consistent with pricing assumptions.
• Total medical customers grew 2% year-to-date to 18.5 million, with strong growth in the select segment (<500 employees).

Capital Management:

• Reduced debt-to-capitalization ratio by ~100 basis points to 41.8% as of September 30, 2026.
• Repurchased ~900,000 shares for ~$250 million in Q3.
• On track to achieve a long-term debt-to-capital target of ~40% by year-end 2026.

Accelerate to One Initiative:

• Announced a modernization and productivity initiative aimed at generating $3 billion in gross run-rate savings by 2030.
• Savings will be derived from automation, process modernization, talent effectiveness (~70-80%), and vendor management (~20-30%).
• Some savings will be reinvested in growth/innovation, while others will benefit operating results.

Evernorth Health Services: Reported adjusted revenues of $63.8 billion, representing a 6% year-over-year growth. Pre-tax adjusted earnings were $1.8 billion. Within this segment, Specialty and Care Services delivered pre-tax adjusted earnings of $1.1 billion (a 15% year-over-year increase), while Pharmacy Benefit Services reported pre-tax adjusted earnings of $765 million, in line with expectations. Cigna Healthcare: Reported adjusted revenues of $11.7 billion, reflecting a 9% year-over-year growth. Pre-tax adjusted earnings were $1.2 billion, exceeding expectations due to favorable net investment income and operating efficiencies. The medical care ratio remained stable at 85%, consistent with expectations.

• Raised full-year 2026 adjusted EPS outlook to at least $30.60, up from previous estimates, citing strong Q3 performance.
• Maintained full-year 2026 Evernorth pre-tax adjusted earnings guidance of at least $6.9 billion.
• Raised full-year 2026 Cigna Healthcare pre-tax adjusted earnings outlook to at least $4.6 billion.
• Updated full-year 2026 Medical Care Ratio (MCR) midpoint to 84.2%, tightening the range to +/- 25 basis points.
• Provided directional guidance for 2027: Expect adjusted EPS growth of at least 10% off a 2026 run rate of ~$30 (excluding ACA exchange exit impact).
• For 2027 segments: Expect Evernorth earnings to grow low single digits; expect Cigna Healthcare adjusted income from operations to grow within the long-term target of 6%-9% of reported 2026 results (or above high end after adjusting for ACA exit); expect Specialty and Care Services earnings growth near the low end of the 8%-12% long-term target range.
• Reaffirmed long-term goal of 10%-14% average annual adjusted EPS growth and at least $45 adjusted EPS by 2030.

• Regulatory and Legal Risks: Potential administrative costs and burdens associated with complying with evolving regulations, including the Department of Labor’s PBM transparency rule and the Consolidated Appropriations Act of 2026.
• Market and Operational Headwinds: Compression of industry-wide rebate pools and lower employer coverage of GLP-1s for weight loss impacting PBS earnings.
• Pipeline Limitations: A more limited pipeline of biosimilar and specialty generic launches in 2027 compared to prior years.
• Strategic Transition Costs: Stranded overhead costs and runoff expenses associated with the exit from the ACA Exchange business, estimated at a ~$200 million headwind.
• Program Specific Risks: Modest downward pressure on Specialty and Care Services earnings in 2027 due to evolved 340B program requirements.
• Execution Risk: Dependency on successful implementation of the 'Signature' model and the 'Accelerate to One' initiative to deliver projected savings and growth.

Q: Lisa Gill (JP Morgan) asked about the progression of the Signature model adoption in 2027 and how it bridges to the expectation of low single-digit Evernorth income growth, noting that PBS appears transitional.

A: Brian Evanko explained that Phase 1 (design) is complete, Phase 2 (build/contracting) is underway with manufacturers and pharmacies, and Phase 3 (adoption) targets the Cigna Fully Insured book on Jan 1, 2027, with broader ramp in 2028. He clarified that the low single-digit growth expectation for Evernorth in 2027 is driven by PBS headwinds (rebate compression and lower GLP-1 coverage), not the Signature transition itself, which is expected to drive growth from 2028-2030.

Q: Kevin Fishbeck (Bank of America) asked if the ~$200 million headwind from the ACA Exchange exit would be recaptured in 2028 and sought visibility on the 2028 specialty pipeline.

A: Ann Dennison stated that the $200 million headwind includes both lost earnings and stranded overhead, and the company aims to eliminate these costs by 2028. Brian Evanko noted that 2027 is a slower year for biosimilar/generic launches, but the longer-term trend remains positive, with the company expecting to return to normal launch volumes and strong secular growth thereafter.

Q: Scott Fidel (Goldman Sachs) inquired about the timing of run-rate savings from the 'Accelerate to One' initiative hitting the 2027 outlook and any one-time costs.

A: Ann Dennison clarified that the $3 billion savings target is over five years (through 2030), with 70-80% coming from automation/talent and 20-30% from vendors. She indicated that most savings will be reinvested rather than flowing immediately to the bottom line, and one-time execution costs are concentrated in severance and are reflected in current disclosures.

Q: Charles Rhyee (TD Cowen) asked about the impact of 340B rule changes and OPPS cuts on Shields Health Solutions.

A: Brian Evanko stated that Accredo’s exposure to 340B is small relative to competitors, and while there is modest pressure in 2027, it is offset by broader specialty growth. Regarding Shields, he noted that complex 340B rules actually increase demand for Shields’ services, and since Shields is an equity investment, its performance does not consolidate into Cigna’s income but provides investment returns.

Q: Elizabeth Anderson (Evercore ISI) asked about stop-loss performance and Jan 1 pricing vs. trends.

A: Brian Evanko highlighted that the stop-loss book is performing well, with margin profile improvements largely achieved in 2026 through price actions. Ann Dennison added that YTD frequency and high-cost claimant trends are stable and in line with expectations, supporting confidence in the MCR range and margin recapture plan for 2027.